Abiraterone acetate (Zytiga®) for mCRPC post ADT

Assessment Status NCPE Assessment Process Complete
Drug Abiratone
Brand Zytiga®
Indication Treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Assessment Process
Rapid review commissioned 03/01/2013
Rapid review completed 01/02/2013
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 26/09/2013
NCPE assessment completed 07/03/2014
NCPE assessment outcome Reimbursement not recommended at the submitted price

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.